REGN

Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
$810.24
+5.25 (+0.65%)
Mkt Cap: 83.47B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield5.1%
Dividend YieldN/A
Market Cap83.47B
Volume578.4K
Recent News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
globenewswire.com · 2026-08-18
REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026
globenewswire.com · 2026-08-18
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
prnewswire.com · 2026-08-18
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
prnewswire.com · 2026-08-18
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN
defenseworld.net · 2026-08-18
Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
globenewswire.com · 2026-08-17

Unlock the Full Deep Scan

9 AI agents analyze REGN across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →